Thomas Graney
Direktor/Vorstandsmitglied bei Mogrify Ltd.
Vermögen: 40 247 $ am 31.05.2024
Profil
Thomas Graney is currently a Non-Executive Director at Mogrify Ltd.
and an Independent External Director at Notable Labs Ltd.
Previously, he served as the Chief Executive Officer & Director at Oxurion NV from 2020 to 2023.
He also held positions as an Independent Non-Executive Director at AC Immune SA, Chief Financial Officer & Senior Vice President at Vertex Pharmaceuticals, Inc. from 2017 to 2018, CFO, Senior VP-Finance & Corporate Strategy at Ironwood Pharmaceuticals, Inc. from 2014 to 2017, Chief Financial Officer & Vice President-Finance at Ethicon, Inc. from 2010 to 2014, and Chief Financial Officer at Tibotec Pharmaceuticals from 2005 to 2008.
Additionally, he was the Chief Financial Officer at Generation Bio Co. Mr. Graney obtained an undergraduate degree from the University of Delaware and an MBA from The Leonard N Stern School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,45% | 08.05.2024 | 40 247 ( 0,45% ) | 40 247 $ | 31.05.2024 |
Aktive Positionen von Thomas Graney
| Unternehmen | Position | Beginn |
|---|---|---|
Mogrify Ltd.
 Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | 02.11.2021 |
Ehemalige bekannte Positionen von Thomas Graney
| Unternehmen | Position | Ende |
|---|---|---|
| OXURION NV | Vorstandsvorsitzender | 28.12.2023 |
| AC IMMUNE SA | Direktor/Vorstandsmitglied | 01.01.2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Finanzdirektor/CFO | 13.12.2018 |
| IRONWOOD PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 13.09.2017 |
Ethicon, Inc.
 Ethicon, Inc. Medical SpecialtiesHealth Technology Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ. | Finanzdirektor/CFO | 01.08.2014 |
Ausbildung von Thomas Graney
| University of Delaware | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| AC IMMUNE SA | Health Technology |
| OXURION NV | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ethicon, Inc.
Ethicon, Inc. Medical SpecialtiesHealth Technology Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ. | Health Technology |
| Tibotec Pharmaceuticals | |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |